Clinical trials: Schizophrenia Relapse
Schizophrenia
Antipsychotic Therapy and First Episode
For schizophrenic patients who remained in remission while on maintenance medication, there may come a point in time when the relative risk for relapse become so low that discontinuation of therapy can be considered.
- Trial name
- NCT00334035
- Testing
- Quetiapine
- Where
- Hong Kong
- Volunteers
- 169 people
- Sponsor
- The University of Hong Kong
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy, tolerability and safety of paliperidone extended release (ER) tablets (between 3 to 12 milligram (mg), once a day) in the prevention of relapse in schizophrenia participants.
- Trial name
- NCT01662310
- Testing
- Paliperidone
- Where
- 14 sites in China
- Volunteers
- 201 people
- Sponsor
- Janssen Research & Development, LLC
Psychosis, Remission
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with…
- Trial name
- GDR (NCT03248180)
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia Relapse, Schizophrenia
Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
About 1 in 100 people will experience an episode of psychosis. Some people will only experience one 'psychotic episode' and about a quarter of people make a full recovery.
- Conditions
- Schizophrenia Relapse, Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- ExPRESS:2 (NCT03558529)
- Volunteers
- 27 people
- Sponsor
- Manchester Academic Health Science Centre
Psychotic Disorder
Speech-based Assessment of Relapse Risk in People With Psychosis
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis.
- Trial name
- TRUSTING-WP4 (NCT07397975)
- Testing
- Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
- Where
- 7 sites in Czechia, Ireland and 4 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Philipp Homan
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia Relapse, Light Pollution
Indoor Artificial Light at Night and the Relapse Risk of Schizophrenia
A randomized crossover trial of ALAN intervention was conducted in patients with chronic schizophrenia in Anhui Mental Health Center from August 15 to September 30, 2022.
- Trial name
- NCT05986409
- Testing
- light cover
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Weizhuo Yi
Schizophrenia
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
1. To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 milligram per day (mg/d) compared with placebo in prevention of relapse in patients with schizophrenia 2.
- Trial name
- NCT03593213
- Testing
- Cariprazine
- Where
- 97 sites in United States, Bulgaria and 9 more
- Volunteers
- 587 people
- Sponsor
- AbbVie
Schizophrenia, Schizoaffective Disorder
Smoking Relapse Prevention in Schizophrenia
This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Smokers
- Trial name
- NCT00320697
- Testing
- bupropion + nicotine patch + nicotine gum or lozenges
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia, Schizophrenia Relapse
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the ten years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with…
- Conditions
- Schizophrenia, Schizophrenia Relapse, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- ADARFEP_10Y (NCT03090490)
- Testing
- Antipsychotic treatment discontinuation, Maintenance treatment discontinuation
- Where
- Spain
- Volunteers
- 68 people
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
PREvent First Episode Relapse (PREFER)
Many patients who have recently received a diagnosis of schizophrenia (e.g., "first-episode schizophrenia") respond very well to their antipsychotic medication when they are acutely ill.
- Trial name
- NCT00220714
- Testing
- atypical antipsychotics:oral vs. long-acting route, Family Psychoeducation
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- State University of New York - Downstate Medical Center
Schizophrenia
Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder
The Joint Crisis Plan = SOS Plan is a reference to a particular form of psychiatric advance directive which involves the patient, the healthcare team, their relatives and a third party caregiver as intermediary for the project.
- Trial name
- SOS (NCT02627716)
- Testing
- SOS Plan
- Where
- 4 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Lille
Schizophrenia, Mental Disorder
Evaluation of a Psychoeducation Program for Families Caregivers of Schizophrenic Patients : Randomized Study in Two Arms
The involvement of family members is crucial and improves the prognosis of psychiatric patients and reinforces therapeutic adherence and reduces the frequency of relapses.
- Conditions
- Schizophrenia, Mental Disorder, Educational Problems, Family Relations
- Trial name
- PSYEDUC (NCT03000985)
- Testing
- Psychoeducation
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Schizophrenia, Schizoaffective Disorder
Texting for Relapse Prevention
The purpose of this study is to examine whether Texting for Relapse Prevention (T4RP), a text messaging-based early warming for relapse prevention in people who have schizophrenia/SAD, is associated with fewer relapse symptoms…
- Trial name
- T4RP (NCT02819349)
- Testing
- Texting for Relapse Prevention (T4RP)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Center for Innovative Public Health Research
Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
- Trial name
- NCT07227818
- Testing
- NBI-1117568
- Where
- 25 sites in United States, Puerto Rico and 1 more
- Volunteers
- 560 people
- Sponsor
- Neurocrine Biosciences